HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development

REFERENCES

• Wensing A. M., Boucher C. A. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5: 140–155
   PubMedGoogle Scholar
• Girard M. P., Bansal G. P. HIV/AIDS vaccines: A need for new concepts?. Int Rev Immunol 2008; 27: 447–471
   PubMed Web of Science ®Google Scholar
• Sekaly R. P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. J Exp Med 2008; 205: 7–12
   PubMed Web of Science ®Google Scholar
• Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., et al. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 2007; 12: 23–48
   PubMed Web of Science ®Google Scholar
• Spearman P. HIV vaccine development: Lessons from the past and promise for the future. Curr HIV Res 2003; 1: 101–120
   PubMedGoogle Scholar
• Amara R. R., Villinger F., Altman J. D., Lydy S. L., O'Neil S. P., Staprans S. I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69–74
   PubMed Web of Science ®Google Scholar
• Bertley F. M., Kozlowski P. A., Wang S. W., Chappelle J., Patel J., Sonuyi O., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004; 172: 3745–3757
   PubMed Web of Science ®Google Scholar
• Crotty S., Miller C. J., Lohman B. L., Neagu M. R., Compton L., Lu D., et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75: 7435–7452
   PubMed Web of Science ®Google Scholar
• Doria-Rose N. A., Ohlen C., Polacino P., Pierce C. C., Hensel M. T., Kuller L., et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 2003; 77: 11563–11577
   PubMedGoogle Scholar
• Malkevitch N., Patterson L. J., Aldrich K., Richardson E., Alvord W. G., Robert-Guroff M. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J. Immunol 2003; 170: 4281–4289
   PubMed Web of Science ®Google Scholar
• Mossman S. P., Pierce C. C., Watson A. J., Robertson M. N., Montefiori D. C., Kuller L., et al. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res Hum Retroviruses 2004; 20: 425–434
   Google Scholar
• Negri D. R., Buffa V., Leone P., Bona R., Borghi M., Carlini F., et al. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J Immunol Methods 2004; 291: 153–163
   Google Scholar
• Zhao J., Lou Y., Pinczewski J., Malkevitch N., Aldrich K., Kalyanaraman V. S., et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 2003; 21: 4022–4035
   PubMed Web of Science ®Google Scholar
• Billich A. AIDSVAX VaxGen. Curr Opin Investig Drugs 2004; 5: 214–221
   PubMedGoogle Scholar
• Letvin N. L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6: 930–939
   PubMedGoogle Scholar
• Robinson H. L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007; 82: 686–693
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4: 199–210
   PubMed Web of Science ®Google Scholar
• Kwong P. D., Doyle M. L., Casper D. J., Cicala C., Leavitt S. A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678–682
   PubMed Web of Science ®Google Scholar
• Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998; 280: 1884–1888
   PubMed Web of Science ®Google Scholar
• Reitter J. N., Means R. E., Desrosiers R. C. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998; 4: 679–684
   PubMed Web of Science ®Google Scholar
• Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H. K., et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259–1265
   PubMed Web of Science ®Google Scholar
• Burton D. R., Desrosiers R. C., Doms R. W., Koff W. C., Kwong P. D., Moore J. P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233–236
   PubMed Web of Science ®Google Scholar
• McMichael A. J., Hanke T. HIV vaccines 1983–2003. Nat Med 2003; 9: 874–880
   PubMed Web of Science ®Google Scholar
• Rambaut A., Posada D., Crandall K. A., Holmes E. C. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52–61
   PubMed Web of Science ®Google Scholar
• Allen T. M., Altfeld M. HIV-1 superinfection. J Allergy Clin Immunol 2003; 112: 829–835
   PubMed Web of Science ®Google Scholar
• Altfeld M., Allen T. M., Yu X. G., Johnston M. N., Agrawal D., Korber B. T., et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002; 420: 434–439
   PubMed Web of Science ®Google Scholar
• Butler I. F., Pandrea I., Marx P. A., Apetrei C. HIV genetic diversity: Biological and public health consequences. Curr HIV Res 2007; 5: 23–45
   PubMed Web of Science ®Google Scholar
• Tebit D. M., Nankya I., Arts E. J., Gao Y. HIV diversity, recombination and disease progression: How does fitness “fit” into the puzzle?. AIDS Rev 2007; 9: 75–87
   PubMed Web of Science ®Google Scholar
• Lubeck M. D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3: 651–658
   PubMed Web of Science ®Google Scholar
• Peng B., Wang L. R., Gomez-Roman V. R., vis-Warren A., Montefiori D. C., Kalyanaraman V. S., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005; 79: 10200–10209
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M., Kaur H., Patterson L. J., Leno M., Conley A. J., McKenna P. M., et al. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol 1998; 72: 10275–10280
   PubMed Web of Science ®Google Scholar
• Sernicola L., Corrias F., Koanga-Mogtomo M. L., Baroncelli S., Di F. S., Maggiorella M. T., et al. Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: No detection of reactivation after stimulation with a recall antigen. Virology 1999; 256: 291–302
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S., Lubeck M., Xu S., Burda S., Natuk R. J., Sinangil F., et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 1998; 72: 1052–1059
   PubMed Web of Science ®Google Scholar
• Buge S. L., Ma H. L., Amara R. R., Wyatt L. S., Earl P. L., Villinger F., et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 2003; 19: 891–900
   Google Scholar
• Beattie T., Rowland-Jones S., Kaul R. HIV-1 and AIDS: What are protective immune responses?. J HIV Ther 2002; 7: 35–39
   Google Scholar
• Douek D. C. Disrupting T-cell homeostasis: How HIV-1 infection causes disease. AIDS Rev 2003; 5: 172–177
   PubMedGoogle Scholar
• Douek D. C., Picker L. J., Koup R. A. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21: 265–304
   PubMed Web of Science ®Google Scholar
• Ferrantelli F., Rasmussen R. A., Buckley K. A., Li P. L., Wang T., Montefiori D. C., et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189: 2167–2173
   PubMed Web of Science ®Google Scholar
• Ferrantelli F., Ruprecht R. M. Neutralizing antibodies against HIV—Back in the major leagues?. Curr Opin Immunol 2002; 14: 495–502
   Google Scholar
• John G. C., Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996; 18: 149–157
   PubMed Web of Science ®Google Scholar
• Kourtis A. P., Butera S., Ibegbu C., Beled L., Duerr A. Breast milk and HIV-1: Vector of transmission or vehicle of protection?. Lancet Infect Dis 2003; 3: 786–793
   Google Scholar
• Kulkarni P. S., Butera S. T., Duerr A. C. Resistance to HIV-1 infection: Lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5: 87–103
   PubMedGoogle Scholar
• Levy J. A. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24: 628–632
   PubMed Web of Science ®Google Scholar
• Levy J. A., Scott I., Mackewicz C. Protection from HIV/AIDS: The importance of innate immunity. Clin Immunol 2003; 108: 167–174
   PubMed Web of Science ®Google Scholar
• Ruprecht R. M., Ferrantelli F., Kitabwalla M., Xu W., McClure H. M. Antibody protection: Passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003; 21: 3370–3373
   PubMed Web of Science ®Google Scholar
• Stiegler G., Katinger H. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 2003; 51: 757–759
   PubMed Web of Science ®Google Scholar
• Richardson T. M., Jr., Stryjewski B. L., Broder C. C., Hoxie J. A., Mascola J. R., Earl P. L., Doms R. W. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 1996; 70: 753–762
   PubMed Web of Science ®Google Scholar
• Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001; 75: 1165–1171
   PubMed Web of Science ®Google Scholar
• Buckner C., Gines L. G., Saunders C. J., Vojtech L., Srivastava I., Gettie A., et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 2004; 320: 167–180
   PubMed Web of Science ®Google Scholar
• Cherpelis S., Shrivastava I., Gettie A., Jin X., Ho D. D., Barnett S. W., Stamatatos L. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 2001; 75: 1547–1550
   PubMed Web of Science ®Google Scholar
• Burton D. R., Stanfield R. L., Wilson I. A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005; 102: 14943–14948
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S. Improving on nature: Focusing the immune response on the V3 loop. Hum Antibodies 2005; 14: 69–72
   PubMedGoogle Scholar
• Barnett S. W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75: 5526–5540
   PubMed Web of Science ®Google Scholar
• Barnett S. W., Srivastava I. K., Kan E., Zhou F., Goodsell A., Cristillo A. D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008; 22: 339–348
   PubMed Web of Science ®Google Scholar
• Barnett S. W., Srivastava I. K., Ulmer J. B., Donnelly J. J., Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005; 7: 1386–1391
   Google Scholar
• Bogers W. M., Davis D., Baak I., Kan E., Hofman S., Sun Y., et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008; 382: 217–225
   PubMed Web of Science ®Google Scholar
• Srivastava I. K., Kan E., Sun Y., Sharma V. A., Cisto J., Burke B., et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 2008; 372: 273–290
   Google Scholar
• Srivastava I. K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003; 77: 11244–11259
   PubMed Web of Science ®Google Scholar
• Srivastava I. K., VanDorsten K., Vojtech L., Barnett S. W., Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003; 77: 2310–2320
   PubMed Web of Science ®Google Scholar
• Srivastava I., Goodsell A., Zhou F., Sun Y., Burke B., Barnett S., Vajdy M. Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine 2008; 26: 2796–2806
   Google Scholar
• Amara R. R., Sharma S., Patel M., Smith J. M., Chennareddi L., Herndon J. G., Robinson H. L. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques. Virology 2005; 334: 124–133
   Google Scholar
• Geels M. J., Dubey S. A., Anderson K., Baan E., Bakker M., Pollakis G., et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): Importance of HLA anchor residue conservation. J Virol 2005; 79: 11247–11258
   PubMed Web of Science ®Google Scholar
• Caputo A., Gavioli R., Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2004; 2: 357–376
   PubMed Web of Science ®Google Scholar
• Ensoli B. Criteria for selection of HIV vaccine candidates—General principles. Microbes Infect 2005; 7: 1433–1435
   Google Scholar
• Ensoli B. Rational vaccine strategies against AIDS: Background and rationale. Microbes Infect 2005; 7: 1445–1452
   Google Scholar
• Ensoli B., Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R., et al. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 2005; 7: 1392–1399
   PubMed Web of Science ®Google Scholar
• Ferrantelli F., Cafaro A., Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 2004; 15: 543–556
   PubMed Web of Science ®Google Scholar
• Benito J. M., Lopez M., Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev 2004; 6: 79–88
   PubMed Web of Science ®Google Scholar
• Brown S. A., Hurwitz J. L., Zhan X., Doherty P. C., Slobod K. S. CD8+ T-cells: Are they sufficient to prevent, contain or eradicate HIV-1 infection?. Curr Drug Targets Infect Disord 2005; 5: 113–119
   Google Scholar
• Genesca M., McChesney M. B., Miller C. J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009; 265: 67–77
   PubMed Web of Science ®Google Scholar
• Kawada M., Tsukamoto T., Yamamoto H., Iwamoto N., Kurihara K., Takeda A., et al. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 2008; 82: 10199–10206
   PubMed Web of Science ®Google Scholar
• Liu J., O'Brien K. L., Lynch D. M., Simmons N. L., La P. A., Riggs A. M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457: 87–91
   PubMed Web of Science ®Google Scholar
• Reynolds M. R., Weiler A. M., Weisgrau K. L., Piaskowski S. M., Furlott J. R., Weinfurter J. T., et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205: 2537–2550
   PubMed Web of Science ®Google Scholar
• Saksena N. K., Wu J. Q., Potter S. J., Wilkinson J., Wang B. Human immunodeficiency virus interactions with CD8+ T lymphocytes. Curr HIV Res 2008; 6: 1–9
   PubMed Web of Science ®Google Scholar
• Watkins D. I. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes—A review. Mem Inst Oswaldo Cruz 2008; 103: 119–129
   Google Scholar
• Althaus C. L., De Boer R. J. Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol 2008; 4: 1–9
   Google Scholar
• Loh L., Petravic J., Batten C. J., Davenport M. P., Kent S. J. Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog 2008; 4: 27–37
   Google Scholar
• Buchbinder S. P., Mehrotra D. V., Duerr A., Fitzgerald D. W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881–1893
   PubMed Web of Science ®Google Scholar
• McElrath M. J., De Rosa S. C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008; 372: 1894–1905
   PubMed Web of Science ®Google Scholar
• Robb M. L. Failure of the Merck HIV vaccine: An uncertain step forward. Lancet 2008; 372: 1857–1858
   PubMed Web of Science ®Google Scholar
• Shiver J. W., Fu T. M., Chen L., Casimiro D. R., Davies M. E., Evans R. K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331–335
   PubMed Web of Science ®Google Scholar
• Valentine L. E., Watkins D. I. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol 2008; 16: 605–611
   Google Scholar
• Watkins D. I., Burton D. R., Kallas E. G., Moore J. P., Koff W. C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14: 617–621
   PubMed Web of Science ®Google Scholar
• Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F. S. Buttò, et al., Candidate HIV-1 Tat vaccine development: From basic science to clinical trials. AIDS 2006; 20: 2245–2261
   PubMed Web of Science ®Google Scholar
• Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008; 22: 2207–2209
   PubMed Web of Science ®Google Scholar
• Appay V., Douek D. C., Price D. A. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623–628
   PubMed Web of Science ®Google Scholar
• Letvin N. L. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 2007; 27: 366–369
   PubMed Web of Science ®Google Scholar
• Pantaleo G., Koup R. A. Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004; 10: 806–810
   PubMed Web of Science ®Google Scholar
• Piacentini L., Fenizia C., Naddeo V., Clerici M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008; 26: 3002–3007
   PubMed Web of Science ®Google Scholar
• Polonis V. R., Brown B. K., Rosa B. A., Zolla-Pazner S., Dimitrov D. S., Zhang M. Y., et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008; 375: 315–320
   PubMed Web of Science ®Google Scholar
• Ferrantelli F., Buttò S., Cafaro A., Wahren B., Ensoli B. Building collaborative networks for HIV/AIDS vaccine development: The AVIP experience. Springer Semin Immunopathol 2006; 28: 289–301
   PubMedGoogle Scholar
• Rodriguez-Chavez I. R., Allen M., Hill E. L., Sheets R. L., Pensiero M., Bradac J. A., D'Souza M. P. Current advances and challenges in HIV-1 vaccines. Curr HIV/AIDS Rep 2006; 3: 39–47
   PubMedGoogle Scholar
• Rollman E., Brave A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005; 7: 1414–1423
   PubMed Web of Science ®Google Scholar
• Wahren B., Ljungberg K., Rollman E., Levi M., Zuber B., Kjerrstrom Z. A., et al. HIV subtypes and recombination strains—Strategies for induction of immune responses in man. Vaccine 2002; 20: 1988–1993
   Google Scholar
• Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M. R., Scoglio A., et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 2009; 182: 2888–2897
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., Ensoli B. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002; 168: 197–206
   PubMed Web of Science ®Google Scholar
• Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008; 26: 727–737
   PubMed Web of Science ®Google Scholar
• Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004; 173: 3838–3843
   PubMed Web of Science ®Google Scholar
• Kittiworakarn J., Lecoq A., Moine G., Thai R., Lajeunesse E., Drevet P., et al. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem 2006; 281: 3105–3115
   PubMed Web of Science ®Google Scholar
• Barillari G., Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002; 15: 310–326
   PubMed Web of Science ®Google Scholar
• Levy J. A. HIV pathogenesis: Knowledge gained after two decades of research. Adv Dent Res 2006; 19: 10–16
   Google Scholar
• Nunnari G., Smith J. A., Daniel R. HIV-1 Tat and AIDS-associated cancer: Targeting the cellular anti-cancer barrier?. J Exp Clin Cancer Res 2008; 27: 3–11
   PubMedGoogle Scholar
• King J. E., Eugenin E. A., Buckner C. M., Berman J. W. HIV tat and neurotoxicity. Microbes Infect 2006; 8: 1347–1357
   PubMed Web of Science ®Google Scholar
• Barillari G., Gendelman R., Gallo R. C., Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A 1993; 90: 7941–7945
   PubMed Web of Science ®Google Scholar
• Brake D. A., Goudsmit J., Krone W. J., Schammel P., Appleby N., Meloen R. H., Debouck C. Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1. J Virol 1990; 64: 962–965
   Google Scholar
• Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674–680
   PubMed Web of Science ®Google Scholar
• Bartz S. R., Emerman M. Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 1999; 73: 1956–1963
   Web of Science ®Google Scholar
• Blazquez M. V., Macho A., Ortiz C., Lucena C., Lopez-Cabrera M., Sanchez-Madrid F., Munoz E. Extracellular HIV type 1 Tat protein induces CD69 expression through NF-kappaB activation: Possible correlation with cell surface Tat-binding proteins. AIDS Res Hum Retroviruses 1999; 15: 1209–1218
   Google Scholar
• Kameoka M., Rong L., Gotte M., Liang C., Russell R. S., Wainberg M. A. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol 2001; 75: 2675–2683
   PubMed Web of Science ®Google Scholar
• Kolson D. L., Buchhalter J., Collman R., Hellmig B., Farrell C. F., Debouck C., Gonzalez-Scarano F. HIV-1 Tat alters normal organization of neurons and astrocytes in primary rodent brain cell cultures: RGD sequence dependence. AIDS Res Hum Retroviruses 1993; 9: 677–685
   PubMedGoogle Scholar
• Ma M., Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997; 71: 2495–2499
   PubMed Web of Science ®Google Scholar
• Mahlknecht U., Dichamp I., Varin A., Van L. C., Herbein G. NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 2008; 83: 718–727
   PubMed Web of Science ®Google Scholar
• Neuveut C., Scoggins R. M., Camerini D., Markham R. B., Jeang K. T. Requirement for the second coding exon of Tat in the optimal replication of macrophage-tropic HIV-1. J Biomed Sci 2003; 10: 651–660
   Google Scholar
• Ott M., Emiliani S., Van L. C., Herbein G., Lovett J., Chirmule N., et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275: 1481–1485
   PubMed Web of Science ®Google Scholar
• Smith S. M., Pentlicky S., Klase Z., Singh M., Neuveut C., Lu C. Y., et al. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem 2003; 278: 44816–44825
   Google Scholar
• Tong-Starksen S. E., Baur A., Lu X. B., Peck E., Peterlin B. M. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs. Virology 1993; 195: 826–830
   Google Scholar
• Verhoef K., Bauer M., Meyerhans A., Berkhout B. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. AIDS Res Hum Retroviruses 1998; 14: 1553–1559
   Google Scholar
• Verhoef K., Klein A., Berkhout B. Paracrine activation of the HIV-1 LTR promoter by the viral Tat protein is mechanistically similar to trans-activation within a cell. Virology 1996; 225: 316–327
   Google Scholar
• Campbell G. R., Senkaali D., Watkins J., Esquieu D., Opi S., Yirrell D. L., et al. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine 2007; 25: 8441–8447
   Google Scholar
• Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M. J., Scoglio A., Ensoli F., et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003; 188: 1171–1180
   PubMed Web of Science ®Google Scholar
• Demirhan I., Chandra A., Mueller F., Mueller H., Biberfeld P., Hasselmayer O., Chandra P. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 2000; 3: 137–143
   Google Scholar
• Krone W. J., Debouck C., Epstein L. G., Heutink P., Meloen R., Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988; 26: 261–270
   PubMed Web of Science ®Google Scholar
• Opi S., Peloponese J. M., Jr., Esquieu D., Watkins J., Campbell G., De M. J., et al. Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine 2004; 22: 3105–3111
   Google Scholar
• Re M. C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De R., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 408–416
   PubMedGoogle Scholar
• Re M. C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., La P. M. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol 1996; 3: 230–232
   Google Scholar
• Re M. C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., La P. M. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001; 21: 81–89
   PubMed Web of Science ®Google Scholar
• Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005; 191: 1321–1324
   PubMed Web of Science ®Google Scholar
• Steinaa L., Sorensen A. M., Nielsen J. O., Hansen J. E. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol 1994; 139: 263–271
   PubMed Web of Science ®Google Scholar
• Tahtinen M., Strengell M., Collings A., Pitkanen J., Kjerrstrom A., Hakkarainen K., et al. DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector. Vaccine 2001; 19: 2039–2047
   PubMed Web of Science ®Google Scholar
• Valvatne H., Szilvay A. M., Helland D. E. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation. AIDS Res Hum Retroviruses 1996; 12: 611–619
   Google Scholar
• Rodman T. C., Lutton J. D., Jiang S., Al-Kouatly H. B., Winston R. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol 2001; 29: 1004–1009
   Google Scholar
• Rodman T. C., To S. E., Hashish H., Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci U S A 1993; 90: 7719–7723
   PubMed Web of Science ®Google Scholar
• Belliard G., Hurtrel B., Moreau E., Lafont B. A., Monceaux V., Roques B., et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine 2005; 23: 1399–1407
   Google Scholar
• Devadas K., Boykins R. A., Hewlett I. K., Wood O. L., Clouse K. A., Yamada K. M., Dhawan S. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection. Peptides 2007; 28: 496–504
   PubMed Web of Science ®Google Scholar
• Lecoq A., Moine G., Bellanger L., Drevet P., Thai R., Lajeunesse E., et al. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy. Vaccine 2008; 26: 2615–2626
   PubMed Web of Science ®Google Scholar
• Mascarell L., Bauche C., Fayolle C., Diop O. M., Dupuy M., Nougarede N., et al. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates. Vaccine 2006; 24: 3490–3499
   PubMed Web of Science ®Google Scholar
• Mayol K., Munier S., Beck A., Verrier B., Guillon C. Design and characterization of an HIV-1 Tat mutant: Inactivation of viral and cellular functions but not antigenicity. Vaccine 2007; 25: 6047–6060
   Google Scholar
• Moreau E., Belliard G., Partidos C. D., Pradezinsky F., Le B. H., Muller S., Desgranges C. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol 2004; 85: 2893–2901
   Google Scholar
• Partidos C. D., Hoebeke J., Moreau E., Chaloin O., Tunis M., Belliard G., et al. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol 2005; 35: 1521–1529
   PubMedGoogle Scholar
• Partidos C. D., Moreau E., Chaloin O., Tunis M., Briand J. P., Desgranges C., Muller S. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity. Eur J Immunol 2004; 34: 3723–3731
   Google Scholar
• Ramirez Y. J., Tasciotti E., Gutierrez-Ortega A., Donayre Torres A. J., Olivera Flores M. T., Giacca M., Gomez Lim M. A. Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice. Clin Vaccine Immunol 2007; 14: 685–692
   PubMed Web of Science ®Google Scholar
• Tikhonov I., Ruckwardt T. J., Hatfield G. S., Pauza C. D. Tat-neutralizing antibodies in vaccinated macaques. J Virol 2003; 77: 3157–3166
   Google Scholar
• Watkins J. D., Lancelot S., Campbell G. R., Esquieu D., De M. J., Opi S., et al. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology, 3: 8–2006
   Google Scholar
• Goldstein G., Tribbick G., Manson K. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 2001; 19: 1738–1746
   Google Scholar
• Addo M. M., Altfeld M., Rosenberg E. S., Eldridge R. L., Philips M. N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A 2001; 98: 1781–1786
   PubMed Web of Science ®Google Scholar
• Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006; 24: 5655–5669
   PubMed Web of Science ®Google Scholar
• Castelli F. A., Houitte D., Munier G., Szely N., Lecoq A., Briand J. P., et al. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively. Eur J Immunol 2008; 38: 2821–2831
   Google Scholar
• Marinaro M., Riccomi A., Rappuoli R., Pizza M., Fiorelli V., Tripiciano A., et al. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 2003; 21: 3972–3981
   PubMed Web of Science ®Google Scholar
• Morris C. B., Thanawastien A., Sullivan D. E., Clements J. D. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response. Vaccine 2001; 20: 12–15
   Google Scholar
• Novitsky V., Cao H., Rybak N., Gilbert P., McLane M. F., Gaolekwe S., et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76: 10155–10168
   Google Scholar
• Ramakrishna L., Anand K. K., Mohankumar K. M., Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 2004; 78: 9174–9189
   PubMed Web of Science ®Google Scholar
• Opi S., Peloponese J. M., Jr., Esquieu D., Campbell G., De M. J., Walburger A., et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem 2002; 277: 35915–35919
   Google Scholar
• Pilkington G. R., Duan L., Zhu M., Keil W., Pomerantz R. J. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: Direct selection from a combinatorial phage display library. Mol Immunol 1996; 33: 439–450
   Google Scholar
• Gregoire C., Peloponese J. M., Jr., Esquieu D., Opi S., Campbell G., Solomiac M., et al. Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein. Biopolymers 2001; 62: 324–335
   PubMed Web of Science ®Google Scholar
• Blazevic V., Ranki A., Mattinen S., Valle S. L., Koskimies S., Jung G., Krohn K. J. Helper T-cell recognition of HIV-1 Tat synthetic peptides. J Acquir Immune Defic Syndr 1993; 6: 881–890
   Google Scholar
• Cao J., McNevin J., Holte S., Fink L., Corey L., McElrath M. J. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003; 77: 6867–6878
   Google Scholar
• Jia M. M., Hong K. X., Chen J. P., Liu H. W., Liu S., Zhang X. Q., et al. CTL responses to regulatory proteins Tat and Rev in HIV-1 B'/C virus-infected individuals. Biomed Environ Sci 2008; 21: 314–318
   Google Scholar
• Novitsky V., Rybak N., McLane M. F., Gilbert P., Chigwedere P., Klein I., et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001; 75: 9210–9228
   PubMedGoogle Scholar
• van Baalen C. A., Pontesilli O., Huisman R. C., Geretti A. M., Klein M. R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78: 1913–1918
   PubMed Web of Science ®Google Scholar
• Jones N. A., Wei X., Flower D. R., Wong M., Michor F., Saag M. S., et al. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 2004; 200: 1243–1256
   PubMed Web of Science ®Google Scholar
• Allen T. M., O'Connor D. H., Jing P., Dzuris J. L., Mothe B. R., Vogel T. U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407: 386–390
   PubMed Web of Science ®Google Scholar
• O'Connor D. H., Allen T. M., Watkins D. I. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol 2002; 21: 659–664
   Google Scholar
• Bayer P., Kraft M., Ejchart A., Westendorp M., Frank R., Rosch P. Structural studies of HIV-1 Tat protein. J Mol Biol 1995; 247: 529–535
   PubMed Web of Science ®Google Scholar
• Arya S. K., Guo C., Josephs S. F., Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229: 69–73
   PubMed Web of Science ®Google Scholar
• Geretti A. M. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19: 1–7
   PubMed Web of Science ®Google Scholar
• Belliard G., Romieu A., Zagury J. F., Dali H., Chaloin O., Le G. R., et al. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals. Vaccine 2003; 21: 3186–3199
   Google Scholar
• Richardson M. W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: Differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 2003; 57: 4–14
   PubMed Web of Science ®Google Scholar
• Borsetti A., Baroncelli S., Maggiorella M. T., Moretti S., Fanales-Belasio E., Sernicola L., et al. Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6Pcy243. Viral Immunol 2009; 22: 117–124
   PubMed Web of Science ®Google Scholar
• Cafaro A., Caputo A., Fracasso C., Maggiorella M. T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5: 643–650
   PubMed Web of Science ®Google Scholar
• Cafaro A., Caputo A., Maggiorella M. T., Baroncelli S., Fracasso C., Pace M., et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 2000; 29: 193–208
   PubMed Web of Science ®Google Scholar
• Cafaro A., Titti F., Fracasso C., Maggiorella M. T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19: 2862–2877
   PubMed Web of Science ®Google Scholar
• Maggiorella M. T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22: 3258–3269
   PubMed Web of Science ®Google Scholar
• Huet T., Dazza M. C., Brun-Vezinet F., Roelants G. E., Wain-Hobson S. A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS 1989; 3: 707–715
   PubMedGoogle Scholar
• Gregoire C. J., Loret E. P. Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates. J Biol Chem 1996; 271: 22641–22646
   Google Scholar
• Peloponese J. M., Jr., Collette Y., Gregoire C., Bailly C., Campese D., Meurs E. F., et al. Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem 1999; 274: 11473–11478
   PubMed Web of Science ®Google Scholar
• Goldstein G., Manson K., Tribbick G., Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000; 18: 2789–2795
   PubMed Web of Science ®Google Scholar
• Pauza C. D., Trivedi P., Wallace M., Ruckwardt T. J., Le B. H., Lu W., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A 2000; 97: 3515–3519
   PubMed Web of Science ®Google Scholar
• Allen T. M., Mortara L., Mothe B. R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76: 4108–4112
   Google Scholar
• Silvera P., Richardson M. W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 2002; 76: 3800–3809
   PubMed Web of Science ®Google Scholar
• Liang X., Casimiro D. R., Schleif W. A., Wang F., Davies M. E., Zhang Z. Q., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005; 79: 12321–12331
   PubMed Web of Science ®Google Scholar
• Demberg T., Florese R. H., Heath M. J., Larsen K., Kalisz I., Kalyanaraman V. S., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007; 81: 3414–3427
   PubMed Web of Science ®Google Scholar
• Florese R. H., Wiseman R. W., Venzon D., Karl J. A., Demberg T., Larsen K., et al. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 2008; 26: 3312–3321
   PubMedGoogle Scholar
• Borsutzky S., Ebensen T., Link C., Becker P. D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 2006; 24: 2049–2056
   PubMed Web of Science ®Google Scholar
• Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 2003; 33: 1548–1556
   PubMed Web of Science ®Google Scholar
• Horn M. E., Pappu K. M., Bailey M. R., Clough R. C., Barker M., Jilka J. M., et al. Advantageous features of plant-based systems for the development of HIV vaccines. J Drug Target 2003; 11: 539–545
   PubMed Web of Science ®Google Scholar
• Webster D. E., Thomas M. C., Pickering R., Whyte A., Dry I. B., Gorry P. R., Wesselingh S. L. Is there a role for plant-made vaccines in the prevention of HIV/AIDS?. Immunol Cell Biol 2005; 83: 239–247
   PubMed Web of Science ®Google Scholar
• Kim T. G., Langridge W. H. Synthesis of an HIV-1 Tat transduction domain-rotavirus enterotoxin fusion protein in transgenic potato. Plant Cell Rep 2004; 22: 382–387
   PubMed Web of Science ®Google Scholar
• Karasev A. V., Foulke S., Wellens C., Rich A., Shon K. J., Zwierzynski I., et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 2005; 23: 1875–1880
   PubMed Web of Science ®Google Scholar
• Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev Vaccines 2007; 6: 203–212
   PubMed Web of Science ®Google Scholar
• Lundholm P., Leandersson A. C., Christensson B., Bratt G., Sandstrom E., Wahren B. DNA mucosal HIV vaccine in humans. Virus Res 2002; 82: 141–145
   PubMed Web of Science ®Google Scholar
• Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R. A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67: 277–287
   PubMed Web of Science ®Google Scholar
• Sparnacci K., Laus M., Tondelli L., Bernardi C., Magnani L., Corticelli F., et al. Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. J Biomater Sci Polym Ed 2005; 16: 1557–1574
   PubMed Web of Science ®Google Scholar
• Caputo A., Brocca-Cofano E., Castaldello A., De Michele R., Altavilla G., Marchisio M., et al. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 2004; 22: 2910–2924
   PubMed Web of Science ®Google Scholar
• Caputo A., Sparnacci K., Ensoli B., Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 2008; 5: 230–242
   PubMedGoogle Scholar
• Voltan R., Castaldello A., Brocca-Cofano E., Altavilla G., Caputo A., Laus M., et al. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 2007; 24: 1870–1882
   PubMed Web of Science ®Google Scholar
• Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J. G., et al. Strong T cell type-1 immune responses to HIV-1 Tat (1–72) protein-coated nanoparticles. Vaccine 2004; 22: 2631–2640
   PubMed Web of Science ®Google Scholar
• Patel J., Galey D., Jones J., Ray P., Woodward J. G., Nath A., Mumper R. J. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine 2006; 24: 3564–3573
   PubMed Web of Science ®Google Scholar
• Guillon C., Mayol K., Terrat C., Compagnon C., Primard C., Charles M. H., et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 2007; 25: 7491–7501
   PubMed Web of Science ®Google Scholar
• Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., et al. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine 2002; 20: 2303–2317
   Google Scholar
• Caputo A., Gavioli R., Altavilla G., Brocca-Cofano E., Boarini C., Betti M., et al. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine 2003; 21: 1103–1111
   PubMed Web of Science ®Google Scholar
• Derossi D., Chassaing G., Prochiantz A. Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol 1998; 8: 84–87
   PubMed Web of Science ®Google Scholar
• Leifert J. A., Holler P. D., Harkins S., Kranz D. M., Whitton J. L. The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes. Gene Ther 2003; 10: 2067–2073
   Google Scholar
• Fawell S., Seery J., Daikh Y., Moore C., Chen L. L., Pepinsky B., Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994; 91: 664–668
   PubMed Web of Science ®Google Scholar
• Schwarze S. R., Hruska K. A., Dowdy S. F. Protein transduction: Unrestricted delivery into all cells?. Trends Cell Biol 2000; 10: 290–295
   PubMed Web of Science ®Google Scholar
• Cho H. I., Kim E. K., Park S. Y., Lee S. K., Hong Y. K., Kim T. G. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 2007; 258: 189–198
   PubMed Web of Science ®Google Scholar
• Giannouli C., Brulet J. M., Gesche F., Rappaport J., Burny A., Leo O., Hallez S. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 2003; 23: 3523–3531
   PubMed Web of Science ®Google Scholar
• Kim D. T., Mitchell D. J., Brockstedt D. G., Fong L., Nolan G. P., Fathman C. G., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159: 1666–1668
   PubMed Web of Science ®Google Scholar
• Shibagaki N., Udey M. C. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002; 168: 2393–2401
   PubMed Web of Science ®Google Scholar
• Shibagaki N., Udey M. C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 2003; 33: 850–860
   PubMed Web of Science ®Google Scholar
• Tanaka Y., Dowdy S. F., Linehan D. C., Eberlein T. J., Goedegebuure P. S. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J Immunol 2003; 170: 1291–1298
   Google Scholar
• Mattner F., Fleitmann J. K., Lingnau K., Schmidt W., Egyed A., Fritz J., et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 2002; 62: 1477–1480
   PubMed Web of Science ®Google Scholar
• Remoli A. L., Marsili G., Perrotti E., Gallerani E., Ilari R., Nappi F., et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 2006; 396: 371–380
   PubMed Web of Science ®Google Scholar
• Areste C., Blackbourn D. J. HIV Tat-mediated transcriptional regulation of proteasome protein cleavage specificity. Biochem J 2006; 396: e13–e15
   Google Scholar
• Cellini S., Fortini C., Gallerani E., Destro F., Cofano E. B., Caputo A., Gavioli R. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. Virol J 2008; 5: 81
   Google Scholar
• Gupta S., Boppana R., Mishra G. C., Saha B., Mitra D. HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J Immunol 2008; 180: 79–88
   PubMed Web of Science ®Google Scholar
• Agwale S. M., Shata M. T., Reitz M. S., Jr., Kalyanaraman V. S., Gallo R. C., Popovic M., Hone D. M. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc Natl Acad Sci U S A 2002; 99: 10037–10041
   Google Scholar
• Caputo A., Brocca-Cofano E., Castaldello A., Voltan R., Gavioli R., Srivastava I. K., et al. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine 2008; 26: 1214–1227
   PubMed Web of Science ®Google Scholar
• Zhao J., Voltan R., Peng B., vis-Warren A., Kalyanaraman V. S., Alvord W. G., et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005; 342: 1–12
   PubMed Web of Science ®Google Scholar
• Brave A., Hinkula J., Cafaro A., Eriksson L. E., Srivastava I. K., Magnani M., et al. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine 2007; 25: 6882–6890
   Google Scholar
• Mooij P., Nieuwenhuis I. G., Knoop C. J., Doms R. W., Bogers W. M., Ten Haaft P. J., et al. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 2004; 78: 3333–3342
   PubMed Web of Science ®Google Scholar
• Fuller D. H., Rajakumar P. A., Wu M. S., McMahon C. W., Shipley T., Fuller J. T., et al. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 2006; 348: 200–215
   PubMed Web of Science ®Google Scholar
• Pal R., Venzon D., Santra S., Kalyanaraman V. S., Montefiori D. C., Hocker L., et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006; 80: 3732–3742
   PubMed Web of Science ®Google Scholar
• Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 1997; 71: 5528–5539
   PubMed Web of Science ®Google Scholar
• Kjerrstrom A., Hinkula J., Engstrom G., Ovod V., Krohn K., Benthin R., Wahren B. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 2001; 284: 46–61
   PubMedGoogle Scholar
• Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A. C., Sandstrom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320–1325
   PubMed Web of Science ®Google Scholar
• Calarota S. A., Leandersson A. C., Bratt G., Hinkula J., Klinman D. M., Weinhold K. J., et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999; 163: 2330–2338
   PubMed Web of Science ®Google Scholar
• Scriba T. J., zur Megede J., Glashoff R. H., Treurnicht F. K., Barnett S. W., van Rensburg E. J. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 2005; 23: 1158–1169
   PubMedGoogle Scholar
• Uberla K., Rosenwirth B., ten H. P., Heeney J., Sutter G., Erfle V. Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J Med Primatol 2007; 36: 2–9
   PubMedGoogle Scholar
• Osterhaus A. D., van Baalen C. A., Gruters R. A., Schutten M., Siebelink C. H., Hulskotte E. G., et al. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17: 2713–2714
   PubMed Web of Science ®Google Scholar
• Gruters R. A., van Baalen C. A., Osterhaus A. D. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002; 20: 2011–2015
   PubMed Web of Science ®Google Scholar
• Stittelaar K. J., Gruters R. A., Schutten M., van Baalen C. A., van A. G., Cranage M., et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002; 20: 2921–2927
   PubMed Web of Science ®Google Scholar
• Verrier B., Le G. R., Taman-Onal Y., Terrat C., Guillon C., Durand P. Y., et al. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 2002; 21: 653–658
   PubMed Web of Science ®Google Scholar
• Amara R. R., Villinger F., Altman J. D., Lydy S. L., O'Neil S. P., Staprans S. I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002; 20: 1949–1955
   PubMed Web of Science ®Google Scholar
• Amara R. R., Villinger F., Staprans S. I., Altman J. D., Montefiori D. C., Kozyr N. L., et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76: 7625–7631
   PubMed Web of Science ®Google Scholar
• Brave A., Johansen K., Palma P., Benthin R., Hinkula J. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant. Vaccine 2008; 26: 5957–5966
   Google Scholar
• Burgers W. A., Chege G. K., Muller T. L., van Harmelen J. H., Khoury G., Shephard E. G., et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009; 90: 468–480
   PubMed Web of Science ®Google Scholar
• Burgers W. A., van Harmelen J. H., Shephard E., Adams C., Mgwebi T., Bourn W., et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006; 87: 399–410
   PubMed Web of Science ®Google Scholar
• De Rose R., Chea S., Dale C. J., Reece J., Fernandez C. S., Wilson K. M., et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: Safety and T cell immunogenicity in macaques. Vaccine 2005; 23: 1949–1956
   PubMed Web of Science ®Google Scholar
• De Rose R., Batten C. J., Smith M. Z., Fernandez C. S., Peut V., Thomson S., et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81: 292–300
   PubMed Web of Science ®Google Scholar
• Egan M. A., Megati S., Roopchand V., Garcia-Hand D., Luckay A., Chong S. Y., et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 2006; 24: 4510–4523
   PubMed Web of Science ®Google Scholar
• Halsey R. J., Tanzer F. L., Meyers A., Pillay S., Lynch A., Shephard E., et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res 2008; 133: 259–268
   PubMed Web of Science ®Google Scholar
• Hel Z., Tsai W. P., Tryniszewska E., Nacsa J., Markham P. D., Lewis M. G., et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 2006; 176: 85–96
   Google Scholar
• Huang Y., Chen Z., Zhang W., Gurner D., Song Y., Gardiner D. F., Ho D. D. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defic Syndr 2008; 47: 403–411
   Google Scholar
• Im E. J., Nkolola J. P., di Gleria K., McMichael A. J., Hanke T. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 2006; 36: 2574–2584
   Google Scholar
• Krohn K., Stanescu I., Blazevic V., Vesikari T., Ranki A., Ustav M. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect 2005; 7: 1405–1413
   PubMed Web of Science ®Google Scholar
• Maggiorella M. T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M. R., Macchia I., et al. Multiprotein genetic vaccine in the SIV-Macaca animal model: A promising approach to generate sterilizing immunity to HIV infection. J Med Primatol 2007; 36: 180–194
   Google Scholar
• Makitalo B., Lundholm P., Hinkula J., Nilsson C., Karlen K., Morner A., et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004; 85: 2407–2419
   PubMed Web of Science ®Google Scholar
• Malm M., Sikut R., Krohn K., Blazevic V. GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine 2007; 25: 3293–3301
   PubMed Web of Science ®Google Scholar
• Martinon F., Brochard P., Ripaux M., Delache B., Auregan G., Vaslin B., Le G. R. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Vaccine 2008; 26: 532–545
   PubMed Web of Science ®Google Scholar
• Putkonen P., Quesada-Rolander M., Leandersson A. C., Schwartz S., Thorstensson R., Okuda K., et al. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 1998; 250: 293–301
   PubMed Web of Science ®Google Scholar
• Rollman E., Mathy N., Brave A., Boberg A., Kjerrstrom A., van Wely C., et al. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Vaccine 2007; 25: 2145–2154
   Google Scholar
• Tryniszewska E., Nacsa J., Lewis M. G., Silvera P., Montefiori D., Venzon D., Hel Z., et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 2002; 169: 5347–5357
   PubMed Web of Science ®Google Scholar
• Vogel T. U., Reynolds M. R., Fuller D. H., Vielhuber K., Shipley T., Fuller J. T., et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 2003; 77: 13348–13360
   PubMed Web of Science ®Google Scholar
• Voss G., Manson K., Montefiori D., Watkins D. I., Heeney J., Wyand M., et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003; 77: 1049–1058
   PubMed Web of Science ®Google Scholar
• Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008; 26: 4819–4829
   PubMed Web of Science ®Google Scholar
• Goepfert P. A., Tomaras G. D., Horton H., Montefiori D., Ferrari G., Deers M., et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25: 510–518
   PubMed Web of Science ®Google Scholar
• Dale C. J., De R. R., Stratov I., Chea S., Montefiori D. C., Thomson S., et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol 2004; 78: 13819–13828
   PubMed Web of Science ®Google Scholar
• Dale C. J., De Rose R., Wilson K. M., Croom H. A., Thomson S., Coupar B. E., et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004; 23: 188–197
   PubMed Web of Science ®Google Scholar
• Ramsay A. J., Kent S. J., Strugnell R. A., Suhrbier A., Thomson S. A., Ramshaw I. A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 1999; 171: 27–44
   PubMed Web of Science ®Google Scholar
• Kelleher A. D., Puls R. L., Bebbington M., Boyle D., French R., Kent S. J., et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20: 294–297
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS vaccines. The first shot in a highly targeted strategy. Science 2004; 306: 1276–1277
   Google Scholar
• Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008; 198: 1482–1490
   PubMed Web of Science ®Google Scholar
• Hinkula J., Lundholm P., Wahren B. Nucleic acid vaccination with HIV regulatory genes: A combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 1997; 15: 874–878
   Google Scholar
• Asakura Y., Hinkula J., Leandersson A. C., Fukushima J., Okuda K., Wahren B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 1997; 46: 326–330
   Google Scholar
• Caselli E., Betti M., Grossi M. P., Balboni P. G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999; 162: 5631–5638
   PubMed Web of Science ®Google Scholar
• Dominici S., Laguardia M. E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., et al. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine 2003; 21: 2073–2081
   PubMed Web of Science ®Google Scholar
• Mascarell L., Fayolle C., Bauche C., Ladant D., Leclerc C. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J Virol 2005; 79: 9872–9884
   PubMedGoogle Scholar
• Bozac A., Berto E., Vasquez F., Grandi P., Caputo A., Manservigi R., et al. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine 2006; 24: 7148–7158
   PubMed Web of Science ®Google Scholar
• Rolland M., Jensen M. A., Nickle D. C., Yan J., Learn G. H., Heath L., et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 2007; 81: 8507–8514
   PubMed Web of Science ®Google Scholar